PLK1在滑膜肉瘤中的表达及其临床意义和预后分析  

Expression of PLK1 in synovial sarcoma and its clinical significance and prognostic analysis

作　　者：李众 梁伟华[1] 张贞 王宁[1] 美尔·吐合塔米什 邹泓[1] 顾文艺 齐妍[1] LI Zhong;LIANG Weihua;ZHANG Zhen;WANG Ning;MEIER Tuhetamishen;ZOU Hong;GU Wenyi;QI Yan(Department of Pathology,School of Medicine,Shihezi University,Shihezi,Xinjiang 832002,China;Australian Institute for Bioengineering and Nanotechnology,University of Queensland,Brisbane 4702,Australia)

机构地区：[1]石河子大学医学院病理系,新疆石河子832002 [2]澳大利亚昆士兰大学生物工程与纳米研究所,澳大利亚布里斯班4702

出　　处：《石河子大学学报（自然科学版）》2020年第4期496-501,共6页Journal of Shihezi University(Natural Science)

基　　金：国家自然科学基金项目(81860471)项目;石河子大学国际科技合作推进计划(GJHZ201710)。

摘　　要：目的通过检测滑膜肉瘤(synovial sarcoma,SS)组织中PLK1的表达,探讨PLK1与滑膜肉瘤患者临床病理参数及预后的相关性。方法收集46例SS石蜡组织样本,包括双相型(BSS)39例,单相纤维型(MFSS)7例,非肿瘤对照组23例,应用免疫组化EVISION法检测PLK1表达。运用连续性校正的卡方检验分析其与临床病理参数(患者性别、年龄、肿瘤直径、肿瘤部位、组织学分型、FNCLCC分级、TNM分期和是否发生转移)之间的相关性,运用Cox回归模型对SS患者生存时间进行单因素及多因素分析,并用Kaplan-Meier法分析PLK1表达与SS患者预后的关系。结果(1)在SS组织中,PLK1蛋白表达的阳性率和强阳性率分别为78.26%和45.65%,其中在MFSS为85.71%和57.14%,在BSS为76.92%和43.59%,而在对照组中PLK1表达较低,与在SS组织中的表达存在明显差异(P<0.001)。(2)PLK1表达与SS患者临床病理参数中的年龄大于20岁(P=0.044)、临床TNM分期III-IV期(P=0.038)和FNCLCC分级III级(P=0.019)之间存在明显相关性。(3)通过Cox单因素回归分析显示:TNM分期III-IV期、PLK1高表达和肿瘤发生转移是影响滑膜肉瘤患者生存时间的危险因素。(4)PLK1高表达患者生存期明显短于PLK1低表达患者(P=0.033)。结论PLK1可能参与了SS发生发展过程,并且与患者不良预后相关,提示PLK1可能成为SS临床治疗的潜在靶点。Objective To detect PLK1 expression in synovial sarcoma(SS)tissues and to investigate the correlation between PLK1 expression and clinicopathological parameters of SS patients.Methods A total of 46 paraffin tissue samples from SS patients were collected,including 39 cases of biphasic synovial sarcoma(BSS)and 7 cases of monophasic fibrous synovial sarcoma(MFSS),23 cases of non-tumor tissues were collected and used as controls.The expression of PLK1 was detected by immunohistochemistry EVISION method.Continuity correction chi-square test was used to analyze the correlation between PLK1 expression and the clinicopathological parameters of SS patients(including gender,age,tumor diameter,tumor site,histological classification,FNCLCC grade,TNM stage and metastasis).Univariate and multivariate analysis of overall survival was performed by Cox regression model.Kaplan-Meier method was used to analyze the relationship between PLK1 expression and prognosis of SS patients.Results(1)PLK1 protein expression positive rate and strong positive rate were 78.26%and 45.65%in SS,85.71%and 57.14%respectively in MFSS,76.92%and 43.59%respectively in BSS.However,the expression of PLK1 was lower in the control and significantly different from that in SS samples(P<0.001).(2)the expression of PLK1 was significantly correlated with the age of SS patients over 20 years(P=0.044),clinical TNM stage III-IV(P=0.038)and FNCLCC grade III(P=0.019).(3)univariate Cox regression analysis showed that TNM stage III-IV,high PLK1 expression and tumor metastasis were the risk factors affecting the survival time of SS patients.(4)the overall survival of SS patients with the high PLK1 expression was significantly shorter than those with low PLK1 expression(P=0.033).Conclusion PLK1 is likely involved in the development of SS and is associated with poor prognosis of SS patients,indicating that PLK1 can be a potential target for molecular targeted therapy of SS.

关 键 词：PLK1 滑膜肉瘤 临床病理参数 预后 免疫组织化学 

分 类 号：R738.5[医药卫生—肿瘤]